Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Targeting BCL-2 in MDS

Amer Zeidan • 10 Sep 2020
SOHO 2020
Myelodysplastic Syndromes Azacitidine Decitabine Luspatercept Venetoclax

Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, discusses agents targeting BCL-2 in the treatment of myelodysplastic syndromes (MDS), including luspatercept as well as an orally available version of decitabine. Dr Zeidan also highlights novel agents investigated in Phase I and II trials, including venetoclax in combination with azacitidine, which targets anti-apoptotic signals within cancer cells and shows promising activity in relapsed/refractory patients with MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Amer Zeidan

1:52
Advances in LR-MDS and HR-MDS in 2023 and beyond
Amer Zeidan • 9 Dec 2023
2:14
Trial updates for luspatercept in LR-MDS: COMMANDS, MEDALIST and ELEMENTS-MDS
Amer Zeidan • 9 Dec 2023
1:45
Real-world data: oral decitabine plus cedazuridine versus IV/SC hypomethylating agents
Amer Zeidan • 9 Dec 2023
2:21
STIMULUS-MDS1: sabatolimab + HMAs in untreated HR-MDS
Amer Zeidan • 9 Dec 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals